CD20 targeting gamma delta T cell engaging therapeutic - Shattuck Labs
Latest Information Update: 20 Mar 2023
At a glance
- Originator Shattuck Labs
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Cancer